Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) shot up this morning in pre-market trading on news that the US FDA has approved the company’s gout drug, called Krystexxa, for patients who do not respond to conventional therapy.  At 8:35 AM EST shares were up 27.24% to $18.78 and 1,032,537 shares have already been traded.  This beats the average volume of 798,131 shares, and also exceeds the company’s 52-week range of $11.20 to $16.62.
-Michael B. Sauter
Powered By iWebRSS.com
No comments:
Post a Comment